Author:
Cornelis Candice,Dondorp Wybo,Bolt Ineke,de Wert Guido,van Summeren Marieke,Brilstra Eva,Knoers Nine,Bredenoord Annelien L.
Abstract
Abstract
Background
Massively parallel sequencing techniques, such as whole exome sequencing (WES) and whole genome sequencing (WGS), may reveal unsolicited findings (UFs) unrelated to the diagnostic aim. Such techniques are frequently used for diagnostic purposes in pediatric cases of developmental delay (DD). Yet policy guidelines for informed consent and return of UFs are not well equipped to address specific moral challenges that may arise in these children’s situations.
Discussion
In previous empirical studies conducted by our research group, we found that it is sometimes uncertain how children with a DD will develop and whether they could come to possess capacities for autonomous decision-making in the future. Parents sometimes felt this brought them into a Catch-22 like situation when confronted with choices about UFs before undergoing WES in trio-analysis (both the parents’ and child’s DNA are sequenced). An important reason for choosing to consent to WES was to gain more insight into how their child might develop. However, to make responsible choices about receiving or declining knowledge of UFs, some idea of their child’s future development of autonomous capacities is needed. This undesirable Catch-22 situation was created by the specific policy configuration in which parents were required to make choices about UFs before being sequencing (trio-analysis). We argue that this finding is relevant for reconfiguring current policies for return of UFs for WES/WGS and propose guidelines that encompass two features. First, the informed consent process ought to be staged. Second, differing guidelines are required for withholding/disclosing a UF in cases of DD appropriate to the level of confidence there is about the child’s future developmental of autonomous capacities.
Conclusion
When combined with a dynamic consent procedure, these two features of our guidelines could help overcome significant moral challenges that present themselves in the situations of children undergoing genomic sequencing for clarifying a DD.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Health (social science),Issues, ethics and legal aspects
Reference27 articles.
1. Shkedi-Rafid S, Dheensa S, Crawford G, Fenwick A, Lucassen A. Defining and managing incidental findings in genetic and genomic practice. Journal of medical genetics. 2014:jmedgenet-2014–102435.
2. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical Genetics and Genomics. Gen Med. 2017;19(2):249–55.
3. Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, et al. Disclosure of incidental findings from next-generation sequencing in pediatric genomic research. Pediatrics. 2013;131(3):564–71.
4. Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 2015;97(1):6–21.
5. Bowdin S, Hayeems R, Monfared N, Cohn RD, Meyn M. The SickKids Genome Clinic: developing and evaluating a pediatric model for individualized genomic medicine. Clin Genet. 2016;89(1):10–9.